Triple-negative breast cancer (TNBC), lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification, represents approximately 15-20% of primary breast cancers 1. This evidence concerns the gene PGR and triple-negative breast carcinoma.